Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06653153 · ClinicalTrials.gov registry record · Phase 3
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
A Phase 3 study of Alzheimers Disease, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 1,400
- Enrollment target
- 20
- Study locations
NCT06653153 is a Phase 3 study of Alzheimers Disease that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 1,400 participants, below the 4,051-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06653153, a Phase 3 study of Alzheimers Disease, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participation to receive open-label remternetug in an extension period.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Remternetug
Study Locations (20)
California
- Neuro-Pain Medical Center - Fresno
- Care Access - Huntington Beach - Huntington Beach
- Inglewood Clinical - Inglewood
- Irvine Clinical Research - Irvine
- Healthy Brain Clinic - Long Beach
- Riverside Clinical - Riverside
- Clinical Trials Research - Sacramento
- Artemis Institute for Clinical Research - San Diego
- Sharp Neurocognitive Research Center - San Diego
- Ray Dolby Brain Health Center - San Francisco
- The Neuron Clinic - San Marcos - San Marcos
- Syrentis Clinical Research - Santa Ana
- Providence Medical Foundation - Santa Rosa
- California Neuroscience Research, LLC - Sherman Oaks
Arizona
- MD First Research - Chandler - Chandler
- Care Access - 801 South Power Road, Mesa - Mesa
- Banner Alzheimer's Institute - Phoenix
- Banner Alzheimer's Institute Tucson - Tucson
Alabama
- Parkway Medical Center - Birmingham
Colorado
- Care Access - Aurora - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2030-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06653153
The ClinicalTrials.gov registry entry for NCT06653153 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,051-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (65% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06653153 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06653153 about?
NCT06653153 is a clinical study titled "A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)". The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-bl...
What is the current status of trial NCT06653153?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,400 participants. The study started on 2024-10-24. Estimated completion is 2030-10.
What conditions does trial NCT06653153 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT06653153?
The interventions under investigation include: Placebo (DRUG), Remternetug (DRUG).
Who is sponsoring clinical trial NCT06653153?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06653153 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.